Exchange: NASDAQ·Updated 04:01 AM EDT
JAZZ logo

JAZZJazz Pharmaceuticals plc

$260.22
$3.30
(1.28%)
Pre-Market
Prev Close $256.92
EarningsAug 3
Mkt Cap$16.05B
Vol2.00
News
all
press releases
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
More News
Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Is JAZZ Still the Best Cannabis Stock After Federal Rescheduling?
Jazz Pharmaceuticals pairs its FDA-approved CBD blockbuster with a diversified drug portfolio, offering medical cannabis exposure despite ongoing pipeline risks.
Zacks
Will Jazz (JAZZ) Beat Estimates Again in Its Next Earnings Report?
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026 Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026 PR Newswire DUBLIN, July 20, 2026 DUBLIN, July 20, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will...
PR Newswire
Axsome's NDA for AXS-12 in Narcolepsy Gets FDA Acceptance
AXSM advances AXS-12 toward potential approval after the FDA accepts its NDA for cataplexy in narcolepsy and sets a May 2027 decision date.
Zacks
Axsome Begins Phase III Study on Solriamfetol for ADHD in Children
AXSM doses the first patient in the phase III FOCUS-2 study of solriamfetol for treating ADHD in children aged six to under 12 years.
Zacks
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
Jazz Pharmaceuticals (JAZZ) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
<
1
2
>

Advertisement|Remove ads.